Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1381

The innovative material that creates green energy through mechanical force.

A new nanotechnology development by an international research team led by Tel Aviv University researchers will make it possible to generate electric currents and voltage within the human body through the activation of various organs (mechanical force). The researchers explain that the development involves a new and very strong biological material, similar to collagen, which is non-toxic and causes no harm to the body’s tissues. The researchers believe that this new nanotechnology has many potential applications in medicine, including harvesting clean energy to operate devices implanted in the body (such as pacemakers) through the body’s natural movements, eliminating the need for batteries.

The study was led by Prof. Ehud Gazit of the Shmunis School of Biomedicine and Cancer Research at the Wise Faculty of Life Sciences, the Department of Materials Science and Engineering at the Fleischman Faculty of Engineering, and the Center for Nanoscience and Nanotechnology, along with his lab team, Dr. Santu Bera and Dr. Wei Ji.

Read more | >

University of Maryland scientists discover that match matters: The right combination of parents in nematode worms can turn a gene off indefinitely.

Evidence suggests that what happens in one generation — diet, toxin exposure, trauma, fear — can have lasting effects on future generations. Scientists believe these effects result from epigenetic changes that occur in response to the environment and turn genes on or off without altering the genome or DNA sequence.

But how these changes are passed down through generations has not been understood, in part, because scientists have not had a simple way to study the phenomenon. A new study by researchers at the University of Maryland provides a potential tool for unraveling the mystery of how experiences can cause inheritable changes to an animal’s biology. By mating nematode worms, they produced permanent epigenetic changes that lasted for more than 300 generations. The research was published on July 9, 2021, in the journal Nature Communications.

Read more | >

Summary: Axonal swelling in the Purkinje cells of mice had no detrimental impact on firing rate or the speed at which axons transmit signals. At peak firing rate, axons with swellings were less likely to fail than those without.

Source: McGill University.

Researchers at McGill University have shown that a brain cell structure previously thought to be pathological in fact enhances cells’ ability to transmit information and correlates with better learning on certain tasks.

Read more | >

To develop its drug, Vir “deliberately isolated an antibody that binds to a part of the virus that is very difficult for the virus to mutate,” he said. That piece of the virus is “conserved, not only in all the variants, but in SARS-1… and in a whole family of coronaviruses.”

Vir knew the variant onslaught was coming, said the company’s executive vice president of research and chief scientific officer, Herbert “Skip” Virgin, M.D., Ph.D. So far, added Scangos, its premise of targeting a conserved site to maintain efficacy against mutations “seems to be holding true.”

Sotrovimab “appears to retain activity against variants of concern” like alpha, beta, gamma, epsilon and iota, the National Institutes of Health noted in recently updated COVID-19 treatment guidelines. Last week, GSK and Vir provided data suggesting that delta also belongs to that list. Updated lab experiment data posted on the preprint repository bioRxiv showed sotrovimab’s activity against 14 variants including the troubling delta variant—which first surfaced in India and appears to spread more rapidly than the already-speedy alpha—was very similar to that against the original SARS-CoV-2 virus.

While several vaccines now stand tall in the fight against COVID-19, therapies—and antibody drugs in particular—have had a decidedly tougher time. Saddled with access issues and beset by fast-emerging variants, firstcomer Eli Lilly has recently been forced to rethink its tactics. Now, GlaxoSmithKline and Vir Biotechnology are applying those lessons to their solo agent sotrovimab.

Continue reading “GSK and Vir, navigating early antibody pitfalls, tout delta variant-busting data for latecomer sotrovimab” | >

Humans are integrating with technology. Not in the future – now. With the emergence of custom prosthetics that make us stronger and faster, neural implants that change how our brains work, and new senses and abilities that you’ve never dreamed of having, it’s time to start imagining what a better version of you might look like.

From reality-enhancing implants to brain-controlled exoskeletons, breakthroughs in bio-tech have fuelled a new fusion of machinery and organic matter.

Read more | >

World Economic Forum Founder Klaus Schwab opens Cyber Polygon 2021 with a warning: “A lack of cybersecurity has become a clear and immediate danger to our society worldwide.”

Giving the welcoming remarks at Cyber Polygon for the second year in a row, Schwab spoke at length about the World Economic Forum’s (WEF) desire to tackle cybersecurity by bringing together a closer merger of corporations, small businesses, and governments.

Last year, Schwab warned, “We all know, but still pay insufficient attention to, the frightening scenario of a comprehensive cyber attack, which would bring a complete halt to the power supply, transportation, hospital services, our society as a whole.”

Read more | >

Using CRISPR-Cas9, the researchers subsequently removed the one copy of the Ndn gene from the 15q dup mouse model to generate mice with a normalized genomic copy number for this gene (15q dupΔNdn mouse). Using this model, they demonstrated that the abnormalities observed in 15q dup mice (abnormal spine turnover rate and decreased inhibitory synaptic input) could be ameliorated.

A research group including Kobe University’s Professor TAKUMI Toru (also a Senior Visiting Scientist at RIKEN Center for Biosystems Dynamics Research) and Assistant Professor TAMADA Kota, both of the Physiology Division in the Graduate School of Medicine, has revealed a causal gene (Necdin, NDN) in autism model mice that have the chromosomal abnormality called copy number variation.

The researchers hope to illuminate the NDN gene’s molecular mechanism in order to contribute towards the creation of new treatment strategies for developmental disorders including autism.

These research results were published in Nature Communications on July 1, 2021.

Continue reading “Researchers discover new genetic driver of autism and other developmental disorders” | >